Cromones are of no benefit in:
- Acute bronchoconstriction
- Anaphylaxis
Cautions
- Discontinue if eosinophilic pneumonia occurs
Cromones provide symptomatic relief in allergic rhinitis and conjunctivitis. They work by stabilising the mast cell membrane, thus reducing the release of histamines and other messenger molecules. This leads to the reduction of allergic responses.
Cromones have an anti-inflammatory effect in some patients, partially in children, however it is not possible to predict who will respond to treatment. The mechanism of action for reducing inflammation is not well understood, and various theories have been postulated.
Cromones may reduce the frequency and severity of asthma attacks when used in combination with inhaled β
2 agonists and inhaled steroids.

No important drug interactions have been identified.
Ensure the patient understands that cromones are a prophylactic treatment, also referred to as a 'preventer' and they should not be used in the treatment of acute bronchospasm. Ensure your patient is being treated with a β2 agonist concurrently.
Ensure that the patent knows how to use an inhaler device (+/- spacer) correctly. Ask them to demonstrate how to use it.
All patents with asthma require an annual asthma review, with either a doctor or asthma nurse specialist.
Withdrawal from cromones should be done gradually over a week – abrupt cessation may bring about asthmatic symptoms.